Please assess the completion status of the following clinical trial:

Trial Title: Clinical and Genomic Factors for Prognosis of AIDS Primary Effusion Lymphoma

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: CASE_ONLY
- Primary Purpose: None
- Time Perspective: RETROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Patients diagnosed with primary effusion lymphoma (HIV seropositive or negative) on or after January 1, 1998 on whom survival status at 2 years post PEL diagnosis is available~* Participants may be enrolled to either or both the clinical or genomic portions of the study~* The minimum data required to be able to include a subject for analysis of clinical prognostic factors are:~  * HIV status, and for HIV subjects include cluster of differentiation (CD)4 count, HIV viral load closest to time of diagnosis~ * Age at PEL diagnosis~ * Gender~ * Stage at diagnosis~ * Treatment of PEL~ * Response to treatment~ * Survival status at 2 years~ * Pathology slides (or paraffin block) for central review~* The minimum data required to be able to include a subject for analysis of genomic prognostic factors are:~  * Availability of a pathologic specimen of PEL that will be submitted for genomic analysis~ * Survival status at 2 years~Exclusion Criteria:~* Patients who do not fulfill the criteria as listed above are ineligible

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Chart review, RNA sequencing, microarray (Type: None): Laboratory Biomarker Analysis. Medical chart review is performed and patient information is collected regarding human immunodeficiency virus HIV/AIDS medical history, staging of AIDS related malignancy, and type of treatment. Previously collected tissue samples are analyzed via RNA sequencing and microarray.

Based on this trial design, predict the completion outcome and termination type (if applicable).